Safety of baricitinib in East Asian patients with moderate ‐to‐severe active rheumatoid arthritis: An integrated analysis from clinical trials

ConclusionIntegrated data show that baricitinib is well ‐tolerated in EA patients with moderate‐to‐severely active RA in the context of demonstrated efficacy, which is generally consistent with safety results of the overall study population.

Source: International Journal of Rheumatic Diseases - November 13, 2019 Category: Rheumatology Authors: Ying ‐Chou Chen, Dae Hyun Yoo, Chang Keun Lee, Ko‐Jen Li, Ji‐Eon Won, Wen‐Shuo Wu, Jinglin Zhong, Claudia Nicolay, Chad Daniel Walls, Yoshiya Tanaka Tags: ORIGINAL ARTICLE Source Type: research